Collaboration Agreements (Tables)

6 Months Ended

Jun. 30, 2017

Summary of Revenue Recognized under Agreement

Amounts recognized as revenue under the Japan Agreement were as follows (in thousands):

		Three Months Ended June 30,				Six Months Ended June 30,
Agreement	Deliverable	2017		2016		2017		2016
Japan	License	$	279	$	43	$	491	$	118
	Milestones		—		10,000		—		10,000
	Total license and milestone revenue		279	$	10,043	$	491	$	10,118
	Collaboration services revenue*		13	$	3	$	24	$	7

When and if available compounds, manufacturing — clinical supplies and committee services have each been identified as separate units of accounting with standalone value and amounts allocable to these elements have been recognized and classified within the Collaboration services revenue line item within the condensed consolidated statements of operations.

Total Arrangement Consideration Allocated to Deliverables along with Associated Deferred Revenue

The total arrangement consideration has been allocated to each of the following deliverables under the Japan Agreement, along with any associated deferred revenue as follows (in thousands):

	Cumulative Revenue Through June 30, 2017		Deferred Revenue at June 30, 2017		Total Consideration Through June 30, 2017
License	$	46,201	$	—	$	46,201
When and if available compounds		23		25		48
Manufacturing--clinical supplies		2,144		—		2,144
Committee services		20		—		20
Total license and collaboration services revenue	$	48,388	$	25	$	48,413

Europe [Member]

Summary of Revenue Recognized under Agreement

Amounts recognized as revenue under the Europe Agreement were as follows (in thousands):

		Three Months Ended June 30,				Six Months Ended June 30,
Agreement	Deliverable	2017		2016		2017		2016
Europe	License	$	3,999	$	3,000	$	7,036	$	6,238
	Milestones		—		—		—		—
	Total license and milestone revenue		3,999		3,000		7,036		6,238
	Collaboration services revenue*	$	432	$	323	$	761	$	671

When and if available compounds, manufacturing — clinical supplies, development services — in progress at the time of signing of the agreement, and committee services have each been identified as a separate unit of accounting with standalone value and amounts allocable to these units have been recognized in revenue as services are performed and classified within the Collaboration services revenue line item within the condensed consolidated statements of operations.

Total Arrangement Consideration Allocated to Deliverables along with Associated Deferred Revenue

The total arrangement consideration has been allocated to each of the following deliverables under the Europe Agreement, along with any associated deferred revenue as follows (in thousands):

	Cumulative Revenue Through June 30, 2017		Deferred Revenue at June 30, 2017		Total Consideration Through June 30, 2017
License	$	419,308	$	—	$	419,308
When and if available compounds		399		399		798
Manufacturing--clinical supplies		10,043		—		10,043
Development services--in progress		33,596		—		33,596
Committee services		290		—		290
Total license and collaboration services revenue	$	463,636	$	399	$	464,035

U.S./RoW [Member]

Summary of Revenue Recognized under Agreement

Amounts recognized as revenue under the U.S./RoW Agreement were as follows (in thousands):

		Three Months Ended June 30,				Six Months Ended June 30,
Agreement	Deliverable	2017		2016		2017		2016
U.S. / RoW and China	License	$	17,074	$	60,154	$	33,406	$	76,579
	Milestones		—		—		—		—
	Total license and milestone revenue		17,074		60,154		33,406		76,579
	Collaboration services revenue*		7,197		15,755		14,167		23,939
	China single unit of accounting**	$	—	$	—	$	—	$	—

Co-development, information sharing, and committee services have been combined into a single unit of accounting because the requirements to share information and serve on committees are useful only in combination with the development services, and because all three items are delivered over the same period while manufacturing — clinical supplies has been identified as a separate unit of accounting with standalone value and amounts allocable to this unit of accounting have been recognized and classified within the Collaboration services revenue line item within the condensed consolidated statements of operations.

All revenues attributable to the China unit of accounting are deferred until all deliverables are met. The China license and collaboration services elements have been combined into a single unit of accounting and consideration allocable to this unit is being deferred due to FibroGen’s retention of manufacturing rights and lack of standalone value.

Total Arrangement Consideration Allocated to Deliverables along with Associated Deferred Revenue

The total arrangement consideration has been allocated to each of the following deliverables under the U.S./RoW Agreement, along with any associated deferred revenue as follows (in thousands):

	Cumulative Revenue Through June 30, 2017		Deferred Revenue at June 30, 2017		Total Consideration Through June 30, 2017
License	$	436,103	$	—	$	436,103
Co-development, information sharing & committee services		104,888		27,701		132,589
Manufacturing--clinical supplies		410		43		453
China-single unit of accounting		—		89,390		89,390
Total license and collaboration services revenue	$	541,401	$	117,134	$	658,535